Clinical trials of pharmacotherapy for spinal cord injury.
Spinal cord injury remains with limited natural recovery and only a few general ineffective treatment options. Recent publications have reported enhanced neurologic recovery with the use of methylprednisolone and GM-1 ganglioside. The results of the Maryland GM-1 Ganglioside Study reported a significant drug effect with respect to the fraction of patients that had a change of two or more Frankel grades from entrance into the study to 1-year follow-up. This study formed the basis for the currently ongoing larger placebo-controlled multicentered study using Sygen GM-1 following acute spinal cord injury. This study has entered 797 patients and is expected to present results in early 1998.
Geisler
F H
FH
Chicago Institute of Neurosurgery and Neuroresearch, Illinois 60614, USA.
D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005677:G(M1) Ganglioside / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D018579:Patient Selection; D010919:Placebos; D013119:Spinal Cord Injuries / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors
D018696:Neuroprotective Agents; D010919:Placebos; D005677:G(M1) Ganglioside; D008775:Methylprednisolone